Bioscience Vaccines

Bioscience Vaccines Inc., established in 2009, is a life science company concentrated on enhancing vaccine efficacy. The company was founded by a team including Anthony Hubbard, Amy Overby, Rae Record Ritchie, and chief scientific officer Mark Suckow. Dr. Suckow, also an associate research professor at the University of Notre Dame, has been a key scientific founder, collaborating with the university on the company's core technology. The firm's primary focus is the development and commercialization of vaccine adjuvants, which are supplements designed to boost the immune response and overall effectiveness of vaccines.

The company's core technology is the Matrix Immune Modulator (MIM), which is based on a proprietary extracellular matrix (ECM) technology exclusively licensed from Cook Biotech. This ECM technology, a naturally occurring biomaterial, has a history of use in FDA-cleared products for soft tissue repair. Bioscience Vaccines is repurposing a special formulation of this ECM for use as a vaccine adjuvant. Pre-clinical data has shown that the MIM can increase the potency of certain vaccines, such as the tetanus vaccine, by a significant margin. The business model revolves around developing this MIM technology to be formulated as a companion product for both existing FDA-approved vaccines and those currently in the development pipeline. This positions the company to partner with pharmaceutical and biotech firms, offering a way to improve their vaccine products.

Bioscience Vaccines targets the human and veterinary vaccine markets, with potential applications in treating infectious diseases, preventing cancers, and developing biological warfare vaccines. The company has secured funding to advance its product development, including a $400,000 investment from BioCrossroads' Indiana Seed Fund in 2010 to prepare for a Phase I human clinical trial and to initiate studies for cancer prevention applications. This was followed by an additional $150,000 from the Emerging Innovations Fund in 2011. Headquartered in the Purdue Research Park of West Lafayette, Indiana, the company leverages its strategic partnerships, including with the University of Notre Dame, to drive its research and development efforts.

Keywords: vaccine adjuvant, Matrix Immune Modulator, extracellular matrix technology, infectious disease prevention, cancer vaccines, immunotherapy, biopharmaceutical, life sciences, vaccine efficacy, Cook Biotech, Purdue Research Park, University of Notre Dame, vaccine supplements, clinical trials, biomaterial, tissue regeneration, veterinary vaccines, human vaccines, immune response, biological warfare vaccines